A new systematic review and meta-analysis indicates that hepatitis C is most notably also associated with B-cell non–Hodgkin lymphoma.

A quick overview of our reporting on the 53rd International Liver Congress in Vienna

Recent research shows about 1 in 4 people in the United States have fatty liver disease. Among Latinos, the rate is significantly higher.

A look at the supply chain that results in very high costs for HIV and hepatitis C medications.

Indianapolis native Matt Heskett beat both opioid addiction and hep C. Now he’s paying his good fortune forward with activism and education.

Researchers reviewed numerous studies to inform their detailed tips for better engaging people who inject opioid drugs in hepatitis C care.

Scientists have firmly established an association between direct-acting antiviral treatment and a lower risk of liver cancer and death.

A look at modifiable risk factors that drive non-AIDS cancers, heart attack and end-stage liver and kidney disease in the HIV population

Existing federal law could permit prisons to negotiate a 90 percent–plus discount—without scaring off pharma.

Here are the treatment news stories on Hep with the most views this year